Attached files

file filename
EX-10.282 - RRA 7.25% 2022 NOTES - Endo International plcex10282-endorracounterpart.htm
EX-10.278 - RRA 2019 NOTES - Endo International plcex10278-endoxrracounterpar.htm
EX-10.291 - RRA 2020 NOTES - Endo International plcex10291-endo_xxrraxcounter.htm
EX-10.287 - RRA 2025 NOTES - Endo International plcex10287-endo_rraxcounterpa.htm
EX-10.279 - SUPPLEMENTAL INDENTURE 2020 NOTES - Endo International plcex10279-endosupplementalin.htm
EX-10.288 - SUPPLEMENTAL INDENTURE 2019 NOTES - Endo International plcex10288-endo_supplementalx.htm
EX-10.277 - SUPPLEMENTAL INDENTURE 2019 NOTES - Endo International plcex10277-endoxsuppindenture.htm
EX-10.292 - SUPPLEMENTAL INDENTURE 5.75% 2022 NOTES - Endo International plcex10292-endo_xxsupplementa.htm
EX-10.285 - RRA 2023 NOTES - Endo International plcex10285-endo_rraxcounterpa.htm
EX-10.293 - SUPPLEMENTAL INDENTURE 7.25% 2022 NOTES - Endo International plcex10293-endo_xxsupplementa.htm
EX-10.289 - RRA 2019 NOTES - Endo International plcex10289-endo_rraxcounterpa.htm
EX-10.297 - SUPPLEMENTAL INDENTURE 2025 NOTES - Endo International plcex10297-endo_xxsupplementa.htm
EX-10.283 - SUPPLEMENTAL INDENTURE 5.75% 2022 NOTES - Endo International plcex10283-endosupplementalin.htm
EX-10.280 - RRA 2020 NOTES - Endo International plcex10280-endorracounterpart.htm
EX-10.298 - RRA 2025 NOTES - Endo International plcex10298-endo_xxrraxcounter.htm
EX-10.296 - RRA 2023 NOTES - Endo International plcex10296-endo_xxrraxcounter.htm
EX-10.284 - SUPPLEMENTAL INDENTURE 2023 NOTES - Endo International plcex10284-endo_supplementalx.htm
EX-10.290 - SUPPLEMENTAL INDENTURE 2020 NOTES - Endo International plcex10290-endo_xxsupplementa.htm
EX-10.286 - SUPPLEMENTAL INDENTURE 2025 NOTES - Endo International plcex10286-endo_supplementalx.htm
EX-10.295 - SUPPLEMENTAL INDENTURE 2023 NOTES - Endo International plcex10295-endo_xxsupplementa.htm
EX-10.281 - SUPPLEMENTAL INDENTURE 7.25% 2022 NOTES - Endo International plcex10281-endosupplementalin.htm
EX-10.294 - RRA 7.25% 2022 NOTES - Endo International plcex10294-endo_xxrraxcounter.htm
EX-31.1 - CEO SECTION 302 CERTIFICATION - Endo International plcex3116302015ceo302cert.htm
EX-32.1 - CEO SECTION 906 CERTIFICATION - Endo International plcex3216302015ceo906cert.htm
EX-31.2 - CFO SECTION 302 CERTIFICATION - Endo International plcex3126302015cfo302cert.htm
EX-21 - SUBSIDIARIES - Endo International plcex216302015subsidiaries.htm
EX-10.276 - ENDO 2015 PLAN - MATCHED PERFORMANCE AWARD - Endo International plcex10276endo_2015xplanxmatc.htm
EX-10.275 - ENDO 2015 PLAN - PSU AGREEMENT - Endo International plcex10275endo_2015xplanxpsux.htm
EX-10.274 - ENDO 2015 PLAN - RSU AGREEMENT - Endo International plcex10274endo_2015xplanxrsux.htm
10-Q - 10-Q - Endo International plcendp-6302015x10q.htm
EX-10.19.3 - UPS SECOND AMENDMENT TO MSA - Endo International plcex10193-upssecondamendment.htm
EX-10.273 - ENDO 2015 PLAN - OPTION AGREEMENT - Endo International plcex10273endo_2015xplanxopti.htm
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Suketu P. Upadhyay, as Chief Financial Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2015 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ SUKETU P. UPADHYAY
Name:
 
Suketu P. Upadhyay
Title:
 
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
Date: August 10, 2015
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.